Latest Ratings for ARCT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Wells Fargo | Maintains | Overweight | |
| Jan 2022 | Raymond James | Upgrades | Underperform | Market Perform |
| Nov 2021 | Barclays | Maintains | Underweight |
Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views
